Biocompatibility parameters in in-vitro simulated automated versus continuous ambulatory peritoneal dialysis.
BACKGROUND
In peritoneal dialysis, the usage of automated peritoneal dialysis (APD) has been steadily increased. As APD means larger volumes of solution and more frequent contact times with fresh dialysate, an additive negative impact on biocompatibility data, exceeding the known effect of conventional PD fluids, seems possible. For an in-vitro comparison of APD and CAPD, a new cell culture system has recently been established.


METHODS
A double chamber cell culture system with human mesothelial cells on top of a permeable membrane and growth medium beyond was used for mimicking CAPD and APD. Reflecting the in vivo equilibration pattern, we compared an eight-hour CAPD with a CCPD setting, using a conventional PD solution. Cell viability was assessed with a MTT assay and cell function via constitutive and stimulated IL-6 release. CA125 was measured as a parameter of mesothelial cell integrity, and TGF-1beta was measured as an index of induction of fibrosis.


RESULTS
Both the CAPD and the CCPD mode resulted in a significantly lower MTT assay and stimulated IL-6 release compared to growth medium. TGF-1beta and CA125 release did not differ between the PD modes and control. The CAPD and the CCPD mode itself did not differ with regard to MTT assay, IL-6 release, TGF-1beta and CA125 generation.


CONCLUSIONS
From the in-vitro model imitating the acute exposure of mesothelial cells with conventional PD fluid in a CCPD and CAPD mode, there is no evidence that APD, due to the larger volumes of solution and more frequent contact times with fresh dialysate, has an acute, additive negative impact on biocompatibility parameters indicative for peritoneal host defense, mesothelial cell integrity and peritoneal fibrosis.
Fusshoeller
A
A
Department of Nephrology, Heinrich Heine University of Düsseldorf, Germany. Andreas.Fusshoeller@uni-duesseldorf.de
Baehr
J
J
Tiemann
B
B
Grabensee
B
B
Plum
J
J
D018394:CA-125 Antigen / Q000032:analysis / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003198:Computer Simulation; D015314:Dialysis Solutions / Q000737:chemistry*; D004797:Enzyme-Linked Immunosorbent Assay; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000032:analysis / Q000378:metabolism; D008422:Materials Testing / Q000379:methods*; D009852:Omentum / Q000166:cytology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000378:metabolism
D018394:CA-125 Antigen; D015314:Dialysis Solutions; D015850:Interleukin-6; D016212:Transforming Growth Factor beta